Amended FDA Protocol Submitted for Phase 2b Trial of Advanced Alzheimer’s Therapy

Amended FDA Protocol Submitted for Phase 2b Trial of Advanced Alzheimer’s Therapy
NeurotropeNeurotrope BioScience has submitted an amended protocol to the U.S. Food and Drug Administration (FDA) for a Phase 2b clinical trial of its lead product candidate bryostatin-1 for treating advanced Alzheimer's disease. The company said in a press release that in the original trial protocol, the primary efficacy outcome is at week 13, unchanged with this amendment, and the trial's primary efficacy endpoint remains based on the Severe Impairment Battery scale assessment tha
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *